Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
- PMID: 14598082
- DOI: 10.1007/s10072-003-0125-z
Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
Abstract
We examined the potential sex-related differences in levodopa pharmacokinetics and their relation with the presence of dyskinesias in a group of 115 patients (67 men, 49 women) with Parkinson's disease. The patients were given a standard oral dose of levodopa plus benserazide (100/25 mg). The area under the levodopa plasma concentration time curve, corrected for the levodopa test dose (in mg/kg body weight), (AUC(w)) was significantly higher in women than in men, with a reduced oral clearance. No difference in the proportion of men and women experiencing dyskinesias was observed.
Similar articles
-
Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.Neurol Sci. 2002 Sep;23 Suppl 2:S53-4. doi: 10.1007/s100720200066. Neurol Sci. 2002. PMID: 12548340
-
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.Mov Disord. 2005 Jun;20(6):734-9. doi: 10.1002/mds.20410. Mov Disord. 2005. PMID: 15747357 Clinical Trial.
-
Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.Neurosci Lett. 2004 Jun 17;363(3):284-7. doi: 10.1016/j.neulet.2004.04.012. Neurosci Lett. 2004. PMID: 15182961 Clinical Trial.
-
Levodopa-related motor complications--phenomenology.Mov Disord. 2008;23 Suppl 3:S509-14. doi: 10.1002/mds.22021. Mov Disord. 2008. PMID: 18781677 Review.
-
Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.Exp Neurol. 2003 Dec;184(2):556-60. doi: 10.1016/S0014-4886(03)00402-3. Exp Neurol. 2003. PMID: 14769348 Review. No abstract available.
Cited by
-
Exploring gender differences in pharmacokinetics of central nervous system related medicines based on a systematic review approach.Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8311-8347. doi: 10.1007/s00210-024-03190-9. Epub 2024 Jun 8. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38850303
-
Treatment Responsiveness of Motor Features in Parkinson's Disease: A Matched Case-Control Analysis.Mov Disord Clin Pract. 2019 Nov 21;7(1):45-51. doi: 10.1002/mdc3.12856. eCollection 2020 Jan. Mov Disord Clin Pract. 2019. PMID: 31970211 Free PMC article.
-
Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring.J Parkinsons Dis. 2022;12(8):2519-2530. doi: 10.3233/JPD-223374. J Parkinsons Dis. 2022. PMID: 36373294 Free PMC article.
-
IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.Neurodegener Dis Manag. 2013 Apr 1;3(2):123-131. doi: 10.2217/nmt.13.4. Neurodegener Dis Manag. 2013. PMID: 24501594 Free PMC article.
-
Predictors of motor complications in early Parkinson's disease: A prospective cohort study.Mov Disord. 2019 Aug;34(8):1174-1183. doi: 10.1002/mds.27783. Epub 2019 Jul 8. Mov Disord. 2019. PMID: 31283854 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical